CD4 + T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein-Barr virus genes.

Sidorov, Semjon; Fux, Lara; Steiner, Katja; Bounlom, Samyo; Traxel, Sabrina; Azzi, Tarik; Berisha, Arbeneshe; Berger, Christoph; Bernasconi, Michele; Niggli, Felix K; Perner, Yvonne; Pather, Sugeshnee; Kempf, Werner; Nadal, David; Bürgler, Simone (2022). CD4 + T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein-Barr virus genes. Cancer immunology, immunotherapy : CII, 71(6), pp. 1371-1392. Springer 10.1007/s00262-021-03057-5

[img]
Preview
Text
Sidorov2021_Article_CD4TCellsAreFoundWithinEndemic.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (2MB) | Preview

Endemic Burkitt lymphoma (eBL) is an aggressive B cell cancer characterized by an IgH/c-myc translocation and the harboring of Epstein-Barr virus (EBV). Evidence accumulates that CD4 + T cells might contribute to eBL pathogenesis. Here, we investigate the presence of CD4 + T cells in primary eBL tissue and their potential dichotomous impact on an EBV-infected pre-eBL cell model using ex vivo material and in vitro co-cultures. In addition, we establish a novel method to study the effect of IgH/c-myc translocation in primary B cells by employing a CRISPR/Cas9 knock-in approach to introduce and tag de novo translocation. We unprecedently document that CD4 + T cells are present in primary eBL tumor tissue. Furthermore, we demonstrate that CD4 + T cells on the one hand suppress eBL development by killing pre-eBL cells lacking IgH/c-myc translocation in vitro and on the other hand indirectly promote eBL development by inducing crucial EBV Latency III to Latency I switching in pre-eBL cells. Finally, we show that while the mere presence of an IgH/c-myc translocation does not suffice to escape CD4 + T-cell-mediated killing in vitro, the CD4 + T-cell-mediated suppression of EBV's Latency III program in vivo may allow cells harboring an IgH/c-myc translocation and additional mutations to evade immune control and proliferate by means of deregulated c-myc activity, resulting in neoplasia. Thus, our study highlights the dichotomous effects of CD4 + T cells and the mechanisms involved in eBL pathogenesis, suggests mechanisms of their impact on eBL progression, and provides a novel in vitro model for further investigation of IgH/c-myc translocation.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Paediatric Haematology/Oncology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hämatologie / Onkologie (Pädiatrie)
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hämatologie / Onkologie (Pädiatrie)

UniBE Contributor:

Bernasconi, Michele

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1432-0851

Publisher:

Springer

Language:

English

Submitter:

Anette van Dorland

Date Deposited:

27 Dec 2021 13:34

Last Modified:

05 Dec 2022 15:58

Publisher DOI:

10.1007/s00262-021-03057-5

PubMed ID:

34668039

Uncontrolled Keywords:

CRISPR/CAS9 Endemic Burkitt lymphoma Epstein–Barr virus IgH/c-myc translocation Latency III to Latency I switch T helper cells

BORIS DOI:

10.48350/162785

URI:

https://boris.unibe.ch/id/eprint/162785

Actions (login required)

Edit item Edit item
Provide Feedback